What is the recommended schedule, tool, and follow‑up for screening postpartum women for postpartum depression?

Postpartum Depression Screening Recommendations

Use the Edinburgh Postnatal Depression Scale (EPDS) as your primary screening tool for postpartum depression, as it is the only Class A recommended instrument with the strongest psychometric validation. 1

Recommended Screening Tool

The EPDS is unequivocally the best available screening measure for maternal postpartum depression, demonstrating adequate content validity and sufficient internal consistency with structural validity 1. Among 10 validated screening tools evaluated using rigorous COSMIN criteria, only the EPDS received a Class A recommendation; all other tools received Class B recommendations, indicating they require further research before routine use 1.

While the UK National Institute for Health and Care Excellence mentions both the EPDS and PHQ-9 as options 1, and the PHQ-9 shows reasonable specificity (82-84% sensitivity, 84% specificity with simple scoring) 2, the EPDS has superior validation specifically in postpartum populations.

Screening Schedule and Timing

Screen at multiple time-points throughout the first postpartum year, beginning soon after delivery:

• Initial screen: 2-5 days postpartum (immediate postpartum period)
• Subsequent screens: At well-child visits occurring at 2,4,6, and 9 months postpartum 3

This multi-point approach is critical because postpartum depression affects approximately 15% of women during the first postpartum year 1, and symptoms may emerge at different times. However, exercise caution with immediate postpartum screening (within 2-5 days): while the EPDS shows high negative predictive value (99% for ruling out major depression at 6 weeks), it has low positive predictive value (14%), meaning elevated scores often reflect transient postpartum distress rather than confirmed disorder 4.

Screening Cut-off Scores

Use these evidence-based thresholds:

• EPDS ≥10: Standard threshold for identifying women requiring follow-up evaluation 4
• EPDS ≥16: Optimal for detecting major depressive episodes (71% sensitivity, 84% specificity) 4
• EPDS ≥14: Optimal for detecting any mental disorder (65% sensitivity, 73% specificity) 4

Two-Stage Screening Approach

Consider implementing a two-stage procedure for efficiency:

1. Stage 1: Administer a 2-question screen (100% sensitivity, 44% specificity) 2
2. Stage 2: If positive, follow with full EPDS or PHQ-9 for confirmation 2

The 2-question screen captures all cases but generates false positives, while the EPDS provides specificity for accurate identification. This tiered approach optimizes both sensitivity and resource utilization 4, 5.

Clinical Settings for Screening

Screen in multiple healthcare settings where postpartum women access care:

• Primary care clinics
• Pediatric well-child visits (38% completion rate during visits, with 29% by mail and 33% by telephone) 2
• Obstetric postpartum visits
• Psychiatric settings (though optimal patterns require further definition) 3

Pediatric well-child visits offer particular advantage since mothers attend these appointments regularly during the first year, providing natural screening opportunities 3, 2.

Follow-up and Referral Pathways

Critical caveat: Screening without follow-up is ineffective and potentially harmful. 3

For positive screens (EPDS ≥10):

1. Immediate action: Conduct diagnostic evaluation using structured clinical interview (e.g., MINI or SCID) to confirm diagnosis 4
2. Mild to moderate depression: Initiate cognitive-behavioral therapy (strongly recommended) 5
3. Severe depression: Consider antidepressant medication (sertraline or escitalopram as first-line per ACOG 2023 guidelines) 6
4. Therapy-resistant or life-threatening severe depression: Electroconvulsive therapy is strongly recommended 5

For negative screens: Reassure but continue screening at subsequent time-points, as depression can emerge later in the postpartum year.

Important Clinical Pitfalls

Avoid these common errors:

• Don't screen without established follow-up mechanisms - this is the most critical failure point in screening programs 3
• Don't rely solely on immediate postpartum screening - transient distress inflates false positives in the first week 4
• Don't assume one negative screen rules out future risk - screen repeatedly throughout the first year 3
• Don't forget suicide risk assessment - suicide is the second leading cause of maternal mortality in the US 1

Rationale for Universal Screening

Early detection and treatment minimize disease severity and associated morbidity 1. Given that postpartum depression affects 15-22% of women 1, 2 and suicide represents a leading cause of maternal mortality 1, universal screening is justified despite some controversy about optimal implementation 7, 8.

The EPDS is an inexpensive, validated tool that can screen large numbers of postpartum women in community settings to identify those at greatest risk who would benefit most from intervention 1.